Literature DB >> 15552270

Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.

Michael G Alexandrakis1, Freda J Passam, Emmanuel Ganotakis, Evgenios Dafnis, Constantina Dambaki, John Konsolas, Despina S Kyriakou, Efstathios Stathopoulos.   

Abstract

There is evidence that angiogenesis plays an important role in the progression of multiple myeloma (MM). Hepatocyte growth factor (HGF) and tumor necrosis factor-alpha (TNF-alpha) are cytokines that potently stimulate angiogenesis. We evaluated the microvascular density (MVD) of bone marrow biopsies (after immunostaining with anti-CD34 antibodies) and serum levels of HGF and TNF-alpha in 43 patients with newly diagnosed MM. Twenty-four of these patients reached a plateau phase after treatment and were reevaluated for MVD, HGF and TNF-alpha. MVD values and serum levels of HGF and TNF-alpha were elevated in newly diagnosed MM patients in comparison with healthy controls. Pre-treatment MVD, HGF and TNF-alpha increased with advancing stage of MM disease. In patients reaching the plateau phase, a significant reduction in MVD, HGF and TNF-alpha levels occurred. A positive correlation was noted between pre-treatment MVD and serum levels of TNF-alpha and lactic dehydrogenase but not with HGF. However, HGF strongly correlated with beta2-microglobulin (beta2M), TNF-alpha and lactate dehydrogenase (LDH). We conclude that angiogenesis in MM, as expressed by the bone marrow MVD and the serum levels of angiogenic molecules such as HGF and TNF-alpha, increases with advancing clinical stage and decreases after effective chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15552270     DOI: 10.1515/CCLM.2004.230

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.

Authors:  G Tsirakis; C A Pappa; F E Psarakis; M Fragioudaki; C Tsioutis; E Stavroulaki; A Boula; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

2.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

Review 3.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.

Authors:  Roger Abounader; John Laterra
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

4.  Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.

Authors:  Michael G Alexandrakis; Ioannis K Neonakis; Constantina A Pappa; Ioannis Konsolas; Maria Kokonozaki; Rodanthi Vyzoukaki; Stella Soundoulounaki; Athina Xekalou; Katerina Sfiridaki; George Tsirakis
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-13       Impact factor: 4.553

5.  Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.

Authors:  K Sfiridaki; C A Pappa; G Tsirakis; P Kanellou; M Kaparou; M Stratinaki; G Sakellaris; G Kontakis; M G Alexandrakis
Journal:  Mediators Inflamm       Date:  2011-09-18       Impact factor: 4.711

6.  Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.

Authors:  Sebastian Gonzalez-McQuire; Meletios-Athanassios Dimopoulos; Katja Weisel; Walter Bouwmeester; Roman Hájek; Marco Campioni; Craig Bennison; Weiwei Xu; Krystallia Pantiri; Marja Hensen; Evangelos Terpos; Stefan Knop
Journal:  MDM Policy Pract       Date:  2019-01-17

7.  BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.

Authors:  L Bolkun; D Lemancewicz; E Jablonska; A Kulczynska; U Bolkun-Skornicka; J Kloczko; J Dzieciol
Journal:  Ann Hematol       Date:  2013-10-19       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.